Last reviewed · How we verify
Batroxobin combined with low molecular weight heparin
Batroxobin combined with low molecular weight heparin is a Small molecule drug developed by Capital Medical University. It is currently FDA-approved.
At a glance
| Generic name | Batroxobin combined with low molecular weight heparin |
|---|---|
| Sponsor | Capital Medical University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Randomized Trial of Anticoagulation Plus Batroxobin for Acute Cerebral Venous Thrombosis (PHASE4)
- The Efficacy and Safety of Batroxobin Combined With Anticoagulation in Cerebral Venous Sinus Thrombosis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Batroxobin combined with low molecular weight heparin CI brief — competitive landscape report
- Batroxobin combined with low molecular weight heparin updates RSS · CI watch RSS
- Capital Medical University portfolio CI
Frequently asked questions about Batroxobin combined with low molecular weight heparin
What is Batroxobin combined with low molecular weight heparin?
Batroxobin combined with low molecular weight heparin is a Small molecule drug developed by Capital Medical University.
Who makes Batroxobin combined with low molecular weight heparin?
Batroxobin combined with low molecular weight heparin is developed and marketed by Capital Medical University (see full Capital Medical University pipeline at /company/capital-medical-university).
What development phase is Batroxobin combined with low molecular weight heparin in?
Batroxobin combined with low molecular weight heparin is FDA-approved (marketed).